Keratoacanthoma
☆ U rezultatima Stiftung Warentest-a za 2022. iz Njemačke, zadovoljstvo potrošača ModelDerm-om bilo je samo nešto niže nego s plaćenim telemedicinskim konsultacijama.
Tipično Keratoacanthoma
References
Keratoacanthoma (KA) je čest tumor kože poznat po brzom rastu i potencijalu da se sam povuče. Obično se javlja kod starijih muškaraca svijetle puti s istorijom oštećenja od sunca. Iako je kirurško uklanjanje pomoću ekscizije ili Mohsove mikrografske operacije uobičajeno liječenje, postoje razne druge mogućnosti terapije.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) je tumor niskog stupnja koji počinje u određenim žlijezdama na koži i izgleda slično squamous cell carcinoma (SCC) pod mikroskopom. U toku je debata o tome da li KA treba klasifikovati kao oblik invazivnog SCC.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) je drugi najčešći tip raka kod ljudi, posebno kod starijih osoba. Hirurgija se obično koristi za liječenje cSCC, ali za neke pacijente koji ne mogu podvrgnuti operaciji ili odluče da to ne urade, mogu se razmotriti i druge opcije poput intralezijskog liječenja. Korišteni su tradicionalni intralezijski tretmani (methotrexate or 5-fluorouracil) , ali su u tijeku istraživanja o novim pristupima kao što su intralezijska imunoterapija i onkolitička viroterapija. Ovdje ćemo pogledati različite intralezijske tretmane za cSCC, u rasponu od klasičnih metoda do najsavremenijih strategija.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Pod mikroskopom, keratoacanthoma veoma liči na karcinom skvamoznih ćelija. Dok neki patolozi klasifikuju keratoacanthoma kao poseban entitet, a ne malignitet, oko 6% kliničkih i histoloških keratoacanthoma napreduje u invazivne i agresivne karcinome skvamoznih ćelija.
○ Dijagnoza i liječenje
#Dermoscopy
#Skin biopsy